Vanguard Fiduciary Trust
BTAI icon

Vanguard Fiduciary Trust’s BioXcel Therapeutics BTAI Stock Holding History

Vanguard Fiduciary Trust’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$193K Buy
136,937
+52,016
+61% +$60.9K ﹤0.01% 3589
2026
Q1 		$114K Buy
+84,921
New +$140K ﹤0.01% 3685

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
P
&Partners Nashville, Tennessee $24.4B AUM 27.45% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Fiduciary Trust's BTAI Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its BioXcel Therapeutics (BTAI) stake by 61% in Q2 2026, buying an estimated $60.9K and bringing the position to 136,937 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #3589.

Vanguard Fiduciary Trust first reported a position in BTAI in Q1 2026 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Vanguard Fiduciary Trust held 136,937 shares of BioXcel Therapeutics worth $193K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 52,016 BioXcel Therapeutics shares in Q2 2026, an estimated $60.9K.
  • BioXcel Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3589 holding.
  • Vanguard Fiduciary Trust first reported a position in BioXcel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.